AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 08:53:00 19/01/2026 pm IST			5-day change	1st Jan Change
13,967.00 ^GBX	-0.60%		-1.16%	+1.20%

03:13pm	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
02:21pm	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI

ASTRAZENECA : JP Morgan remains its Buy rating

Published on 12/08/2025 at 12:32 pm IST

MarketScreener with dpa-AFX Analyser

AstraZeneca PLC

-0.60%

Richard Vosser from JP Morgan retains his positive opinion on the stock with a Buy rating. The target price is revised upwards from GBX 16000 to GBX 14000.

Latest news about AstraZeneca PLC

03:13pm	Daiichi Sankyo and AstraZeneca cheer EU milestone for cancer drug	AN
02:21pm	European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer	CI
02:07pm	Stockholm Bullets - Saab Rises Amid Global Uncertainty	FW
16/01	ASTRAZENECA : Buy rating from UBS	ZD
16/01	ASTRAZENECA : Deutsche Bank gives a Sell rating	ZD
16/01	BofA cuts British Land; RBC raises Gym Group	AN
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update	DJ
15/01	Emergent BioSolutions' Former CEO Sued for Insider Trading by New York Attorney General	MT
15/01	N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading	DJ
15/01	Stocks in green as US manufacturing surprises	AN
15/01	Pharma sector doubles down on AI amid hopes of slashing costs, timelines	RE
15/01	European Equities Traded in the US as American Depositary Receipts Little Changed in Thursday Trading	MT
15/01	AstraZeneca, Abu Dhabi Biobank to Advance Precision Medicine, New Healthcare Practices	MT
15/01	ASTRAZENECA : Barclays reiterates its Buy rating	ZD
15/01	ASTRAZENECA : Gets a Buy rating from JP Morgan	ZD
15/01	Swedish Stocks in North America - Ericsson Down 0.7 Percent	FW
15/01	Sector Update: Health Care Stocks Higher Late Afternoon	MT
15/01	Sector Update: Health Care Stocks Advance in Afternoon Trading	MT
14/01	Sanofi CEO says expects flu-COVID combo vaccines in 2027-2028 to drive next surge in vaccine uptake	RE
14/01	London's FTSE 100 notches new high on mining, healthcare boost	RE
14/01	European Stocks Close Mixed in Wednesday Trading; Rising UK Business Growth 'Good Omen'	MT
14/01	Bonesupport Surges on Preliminary Figures, OMXS30 Index Closes Flat	FW
14/01	US, European regulators set principles for 'good AI practice' in drug development	RE
14/01	Sector Update: Health Care Stocks Mixed Premarket Wednesday	MT
14/01	Sector Update: Health Care	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (94.2%). Net sales break down by treatment area between oncology (39.8%), cardiovascular, renal and metabolic diseases (24.4%), respiratory and autoimmune diseases (14.6%), and other (21.2%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (5.8%). Net sales are distributed geographically as follows: the United Kingdom (8.8%), Europe (21.6%), the United States (40.3%), Americas (5.9%) and Africa/Asia/Australia (23.4%).

Employees

94,300

Sector

Pharmaceuticals

Calendar

10/02 - Q4 2025 Earnings Release

More about the company